
Dr. Michael Moeller, ND
940 posts

Dr. Michael Moeller, ND
@DoctaMoe
☦️ John 8:36 Doctor in SoCal & Idaho Telehealth for Optimization and Longevity Testosterone & Peptides





Steven Bartlett says a few glasses of wine ruined the next 3 days of his life “It's one of those areas where you don't understand the hidden cost until you really give it up for a while. I stopped drinking at 30 years old. I'm now 33. When I was 31, I thought, I'll have a drink again because now I could really A/B test it. I had a year of not drinking, decided to have a drink again” “It ruined three days of my life. I had a couple of glasses of wine, didn't get drunk. It ruined three days of my life because of the domino effect it caused” “I got worse sleep that night, and then because I got worse sleep that night, I ate more poorly the next day because my dopamine system or whatever, the cortisol system was all messed up. I podcasted worse. I didn't go to the gym that day or the day after because I felt really bad. I then slept worse, and I could track all of this on my Whoop”

A man with a testosterone level of 298 can qualify for TRT. A man with a testosterone level of 312 often can't. Same symptoms. Same risks. Completely different outcomes. The problem isn't testosterone. The problem is how we're diagnosing it. In this video, I break down why current low testosterone guidelines may be failing millions of men, the ongoing decline in testosterone levels across the population, and why the future of hormone optimization could look very different than it does today. Plus, I'm taking you inside the Enhanced Games to explore one of the most controversial questions in modern medicine: What happens when we stop limiting human performance? Watch the full video below 👇 #TRT #Testosterone #MensHealth #HormoneOptimization #LowTestosterone #Biohacking #EnhancedGames

















The world’s most popular weight-loss and diabetes drugs are linked to a powerful new possible benefit: better outcomes for cancer patients. on.wsj.com/3RBfcXO







These numbers are shocking. It's like we got a new frontier AI model but for the body. Lilly's phase 3 results for retatrutide: > highest dose lost 28.3% of body weight in 80 wks > 70 lbs ave > 45% lost 30% or more of their body weight > 65% on the top dose no longer clinically obese Retatrutide is more dynamic than semaglutide and tirzepatide because it targets three receptors (GIP, GLP-1, and glucagon), versus one and two, respectively. Side effects, on the highest dose (12mg), were higher for retatrutide than tirzepatide (nausea and GI), with an 11.3% drop out rate. The lowest 4mg dose still delivered 19% loss with fewer dropouts than placebo.



